Dedicated Nuclear Medicine Breast Imaging Device
Award last edited on: 4/15/02

Sponsored Program
Awarding Agency
Total Award Amount
Award Phase
Solicitation Topic Code

Principal Investigator
Gerd Muehllehner

Company Information

UGM Laboratory Inc (AKA: UGM Metals Inc)

3401 Market Street Suite 227
Philadelphia, PA 19104
   (215) 222-7476
Location: Single
Congr. District: 03
County: Philadelphia

Phase I

Contract Number: 1R43CA066514-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
Phase I Amount
Currently, mammography is an important tool in breast cancer screening and has been shown to reduce mortality by early detection. Despite being a very sensitive technique, mammography's specificity is limited in that only approximately 10-30% of mammographically-directed biopsies are positive. Both PET and single-photon Nuclear Medicine imaging studies using Thallium-201, Technetium-99m Sestamibi, and F-18 Fluorodeoxyglucose have been shown to provide sensitive and specific detection of breast cancers. Nuclear Medicine studies would provide cost-effective methods for Secondary breast cancer screening by limiting the number of negative biopsies. For this purpose, we will dedicate Nuclear Medicine breast imaging device based on NaI(T1) detectors capable of performing both PET and singlephoton studies. Since both PET and single-photon radiotracers are likely to play a role in breast cancer detection, a device capable of imaging both tracers is ideally suited to the task. Besides improving the quality of breast imaging over current instrumentation, this device should be sufficiently inexpensive to make Nuclear Medicine breast cancer imaging cost-effective as a secondary screening method. In this Phase I application, we will study the feasibility of this device and begin its overall design.National Cancer Institute (NCI)

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
Phase II Amount